1. In Vivo

New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction

Taking Aim At Recalcitrant Targets

 
• By John Davis

In 2020, investors poured millions of dollars into biotech companies searching for new therapeutics that interact with cellular processes involving the destruction and recycling of cellular proteins. These protein degradation-targeted therapies, and molecular glues, have been attracting the attention of big pharma too.

Test tubes
• Source: Shutterstock

Walking in the woods in the UK would more than likely reveal ash trees marked with colored paint, flagged for felling because of the presence of the lethal “ash dieback” fungus, Hymenoscyphus fraxineus. Having a system of identifying and sorting healthy from diseased trees seems to work well for managing timbered areas – the tagging is specific and tailored to the problem at hand.

The process is not dissimilar to what happens in human cells. Throughout the animal kingdom, a way of marking unneeded...

More from Innovation

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.